What Do We Know About Pain Pathways in Diabetic Peripheral Neuropathy? A Contemporary Narrative Review.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and clinical literature without systematic review methodology
PubMed 42660716 · doi:10.1016/j.clinthera.2026.07.012
What was done
This narrative review searched electronic databases including PubMed and Web of Science for peer-reviewed experimental and clinical studies in English on the pathophysiological mechanisms of painful diabetic peripheral neuropathy (pDPN). The authors evaluated peripheral metabolic and neuroimmune disturbances, nociceptor sensitization pathways, intracellular signaling, and central nervous system plasticity.
What was found
The abstract reports no quantitative metrics or comparative effect estimates. It summarizes biological mechanisms identified in the literature that contribute to pDPN, including hyperglycemia-induced oxidative stress, microvascular insufficiency, mitochondrial dysfunction, ion-channel dysregulation, neuroinflammatory signaling, intracellular kinase activation, Schwann cell injury, and altered central synaptic plasticity.
Why it matters
Understanding the convergence of peripheral nerve pathology and central nervous system changes in painful diabetic neuropathy may help transition clinical care toward mechanism-targeted, individualized therapies.
Limits
The paper is a narrative review with no formal systematic search protocol, quality assessment, or meta-analytic pooling. The abstract provides no specific study counts, patient numbers, or quantitative data.
Cited by
- supports Approximately 50% of people with diabetes develop neuropathy.